Medtronic has globally launched its new guide extension catheter, Telescope, to deliver interventional devices such as coronary stents and balloons during angioplasty procedures.

The device has been designed to offer additional backup support and access to distal lesions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic developed Telescope in alliance with interventional cardiologists to enable improved and smooth delivery of interventional devices in complex cases.

The guide extension catheter features a solid, round pushwire in combination with a coil-reinforced hydrophilic-coated distal segment to enable access to challenging lesions with better pushability and deliverability.

In addition, the device is integrated with a flexible TruFlexsoft polymer tip designed for bending and deflection during use.

It also includes SmoothPass technology for smooth channelling of stents, balloons and other interventional devices into place, after the catheter is in position near the target lesion.

Medtronic Coronary and Renal Denervation business vice-president and general manager Dave Moeller said: “Before bringing this important technology to market, we collaborated with more than 700 interventional cardiologists to ensure Telescope was addressing unmet needs in complex PCI.

“We will continue to make investments in cutting edge interventional technologies, clinical evidence expansion, and robust physician training programmes, which we believe will make a meaningful difference for physicians and their patients.”

“Before bringing this important technology to market, we collaborated with more than 700 interventional cardiologists to ensure Telescope was addressing unmet needs.”

The company’s coronary portfolio additionally includes Resolute Onyx drug-eluting stent (DES), Euphora pre- and post-dilatation balloon catheters range and a suite of catheters including the DxTerity TRA Diagnostic Catheter and Launcher Guide Catheter.

Earlier this month, Medtronic introduced Solitaire X, a revascularisation device intended to treat patients with acute ischemic stroke, in the US.

The device is meant for mechanical removal of blood clots from blocked vessels in the brain. Solitaire X is the company’s fourth generation device.